ストックスクリーナーアプリを入手
13.15
0.98%
-0.13
Neuropace Inc (NPCE) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - marketscreener.com
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
NeuroPace secures $75 million credit facility with MidCap Financial By Investing.com - Investing.com UK
NeuroPace Secures Up to $75 Million in Debt Financing - TradingView
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Cantor Fitzgerald maintains overweight rating on NeuroPace stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains overweight rating on NeuroPace stock - Investing.com
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
NeuroPace, Inc. (NASDAQ:NPCE) Shares Sold by Millennium Management LLC - MarketBeat
Q2 Earnings Estimate for NeuroPace Issued By HC Wainwright - MarketBeat
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $15.50 - Defense World
Q2 Earnings Forecast for NeuroPace Issued By HC Wainwright - Defense World
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Northern Trust Corp - MarketBeat
FY2028 EPS Estimates for NeuroPace Decreased by Analyst - Defense World
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Point72 Asset Management L.P. Takes $369,000 Position in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace (NASDAQ:NPCE) Now Covered by HC Wainwright - Defense World
NeuroPace falls after setback in trial for neuromodulation system - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) Initiates Coverage with "Buy" Rating by HC Wain - GuruFocus
H.C. Wainwright sets $18 target on NeuroPace stock with Buy rating - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Eagle-Tribune
NeuroPace Inc (NPCE) Shares Gap Down to $11.75 on May 28 - GuruFocus
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial - Yahoo Finance
NeuroPace reports initial one-year outcomes from trial of RNS System - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - Nasdaq
Analyst Expectations For NeuroPace's Future - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates NeuroPace at Buy With $18 Price Target - marketscreener.com
Transcript : NeuroPace, Inc.Special Call - marketscreener.com
NeuroPace (NPCE) Receives Positive Initiation from H.C. Wainwrig - GuruFocus
NeuroPace (NPCE) Shares NAUTILUS Study Results on RNS System | N - GuruFocus
NeuroPace reports mixed results in epilepsy study By Investing.com - Investing.com India
Leerink maintains Outperform on NeuroPace stock despite trial data - Investing.com Australia
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? - AOL.com
Cantor Fitzgerald maintains Overweight on NeuroPace shares - Investing.com Australia
Cantor Fitzgerald maintains Overweight on NeuroPace shares By Investing.com - Investing.com India
Leerink maintains Outperform on NeuroPace stock despite trial data By Investing.com - Investing.com Canada
NeuroPace (NASDAQ:NPCE) Reaches New 52-Week HighHere's Why - MarketBeat
0.56%
1.70%
大文字化:
|
ボリューム (24 時間):